The stock of Ophthotech Corp (NASDAQ:OPHT) is a huge mover today! About 1.26 million shares traded hands or 29.72% up from the average. Ophthotech Corp (NASDAQ:OPHT) has declined 29.57% since April 27, 2016 and is downtrending. It has underperformed by 34.80% the S&P500.
The move comes after 5 months negative chart setup for the $1.08B company. It was reported on Nov, 30 by Barchart.com. We have $29.30 PT which if reached, will make NASDAQ:OPHT worth $54.00M less.
Analysts await Ophthotech Corp (NASDAQ:OPHT) to report earnings on February, 22. They expect $-1.46 EPS, down 43.14% or $0.44 from last year’s $-1.02 per share. After $-1.71 actual EPS reported by Ophthotech Corp for the previous quarter, Wall Street now forecasts -14.62% EPS growth.
Ophthotech Corp (NASDAQ:OPHT) Ratings Coverage
Out of 10 analysts covering Ophthotech Corporation (NASDAQ:OPHT), 9 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 90% are positive. Ophthotech Corporation has been the topic of 14 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Citigroup on Thursday, August 4. Stifel Nicolaus maintained Ophthotech Corp (NASDAQ:OPHT) on Thursday, August 6 with “Buy” rating. As per Wednesday, April 27, the company rating was initiated by Barclays Capital. Suntrust Robinson initiated Ophthotech Corp (NASDAQ:OPHT) on Friday, January 8 with “Buy” rating. The stock has “Buy” rating given by Chardan Capital Markets on Tuesday, September 8. The rating was initiated by Citigroup with “Buy” on Thursday, September 3. The stock has “Buy” rating given by SunTrust on Thursday, January 7. The firm earned “Outperform” rating on Friday, August 14 by Oppenheimer. The company was upgraded on Thursday, June 2 by JP Morgan. As per Tuesday, August 4, the company rating was maintained by Chardan Capital Markets.
According to Zacks Investment Research, “Ophthotech Corporation is a biopharmaceutical company. It is focused on developing and commercializing novel therapies for the treatment of diseases of the eye. The Company is developing Fovista and ARC1905, which are under clinical trials, for the treatment of wet AMD. Ophthotech Corporation is headquartered in New York.”
Insitutional Activity: The institutional sentiment decreased to 1.15 in 2016 Q2. Its down 0.80, from 1.95 in 2016Q1. The ratio turned negative, as 21 funds sold all Ophthotech Corp shares owned while 34 reduced positions. 38 funds bought stakes while 69 increased positions. They now own 41.31 million shares or 29.52% more from 31.90 million shares in 2016Q1.
Moreover, Gabelli Funds Limited Liability has 0.01% invested in Ophthotech Corp (NASDAQ:OPHT) for 19,000 shares. Pier Capital Llc has 110,679 shares for 1.03% of their US portfolio. Moreover, Slate Path Capital Limited Partnership has 1.72% invested in Ophthotech Corp (NASDAQ:OPHT) for 430,000 shares. Moreover, Orbimed Advsrs Limited Co has 1.14% invested in Ophthotech Corp (NASDAQ:OPHT) for 2.15 million shares. Moreover, Stifel has 0% invested in Ophthotech Corp (NASDAQ:OPHT) for 17,906 shares. Td Asset Mgmt holds 0% or 43,500 shares in its portfolio. Novo A S has 19.34% invested in the company for 3.61 million shares. The Pennsylvania-based Brandywine Glob Inv Management Lc has invested 0.01% in Ophthotech Corp (NASDAQ:OPHT). D E Shaw has 16,296 shares for 0% of their US portfolio. Rhumbline Advisers reported 30,112 shares or 0% of all its holdings. Artal Grp last reported 0.05% of its portfolio in the stock. The Pennsylvania-based Tfs Capital Ltd Limited Liability Company has invested 0.14% in Ophthotech Corp (NASDAQ:OPHT). Princeton owns 18,452 shares or 0.65% of their US portfolio. Opaleye Management holds 3.51% of its portfolio in Ophthotech Corp (NASDAQ:OPHT) for 8.20M shares. Envestnet Asset last reported 0% of its portfolio in the stock.
Insider Transactions: Since May 31, 2016, the stock had 0 insider buys, and 9 insider sales for $11.42 million net activity. GUYER DAVID R also sold $1.55 million worth of Ophthotech Corp (NASDAQ:OPHT) on Monday, August 1. PATEL SAMIR CHANDRAKANT also sold $2.14 million worth of Ophthotech Corp (NASDAQ:OPHT) shares. Bolte Axel bought $199,395 worth of stock. 671 shares were sold by SBLENDORIO GLENN, worth $38,381.
More important recent Ophthotech Corp (NASDAQ:OPHT) news were published by: Fool.com which released: “Here’s Why Ophthotech Corporation Is Dropping Today” on September 30, 2016, also Fool.com published article titled: “Why Ophthotech Corp. Shares Soared 14.9% in May”, Fool.com published: “Why Ophthotech Corp. Plunged 42% in March” on April 07, 2016. More interesting news about Ophthotech Corp (NASDAQ:OPHT) was released by: Reuters.com and their article: “BRIEF-Ophthotech Corp & Ajinomoto Althea entered into a clinical and comme…” with publication date: November 04, 2016.
OPHT Company Profile
Ophthotech Corporation, incorporated on January 5, 2007, is a biopharmaceutical company. The Firm specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). The Company’s advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV), a specific type of wet AMD. It is also investigating the potential of an ophthalmic formulation for tivozanib, a molecule VEGF tyrosine kinase inhibitor, for which the Company has an option for a license.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.